Every 10-Q that Impact BioMedical, Inc. (IBO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IBO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBO filings page.
Impact BioMedical, a Nevada-based biotechnology company, reported minimal operating revenue and continuing losses for the quarter ended June 30, 2026. Biotech retail sales from its Celios air purification products were $3,000 in the quarter and $10,000 for the first six months of 2026. The company recorded a Q2 net loss of $700,000 and a six-month net loss of $2,983,000, sharply lower than the prior-year periods when a large noncash fair value adjustment and interest on a related-party note drove losses.
Total assets were $16.7 million, dominated by $16.4 million of developed technology and other intangible assets, while cash was only $10,000. Current liabilities were $2.0 million, including $1.33 million due to majority owner DSS, with total stockholders equity of $14.0 million. Operating expenses for the first half rose to $3.0 million, driven by $1.44 million of stock-based compensation, although several cost categories declined. Management disclosed substantial doubt about the companys ability to continue as a going concern and reported that previously identified material weaknesses in internal control over financial reporting remain unresolved.
Impact BioMedical, Inc. reported very limited operating revenue and a larger loss for the quarter ended March 31, 2026. The company generated only $7,000 in biotech retail sales from its Celios air purification products, while total costs and expenses rose to $2,296,000.
Net loss was $2,284,000, compared with $1,278,000 a year earlier, driven mainly by a sharp increase in stock-based compensation to $1,440,000. Cash and cash equivalents were $20,000 at quarter end, and operations were funded partly by $482,000 of new related-party borrowings.
Total assets were $17,086,000, largely made up of $16,709,000 in intangible assets. Accumulated deficit widened to $51,794,000, and management disclosed that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Material weaknesses in internal control over financial reporting remained unremediated.
Impact BioMedical, Inc. (IBO) filed its Q3 2025 10‑Q showing continued operating losses and a going concern warning. The company reported total revenue of $18,000 for the quarter, driven by initial Celios air purification retail sales, and an operating loss of $948,000. Net loss was $1,475,000 for the quarter and $17,105,000 year‑to‑date.
Cash and cash equivalents were $12,000 at September 30, 2025, with net cash used in operating activities of $1,989,000 for the nine months. Current liabilities totaled $23,793,000, including a related‑party note payable measured at $22,881,000, contributing to a total liabilities balance of $27,061,000 and a stockholders’ equity deficit of $8,853,000.
The quarter included amortization expense tied to $17,278,000 of net intangible assets and the first Celios sales after acquiring DSS PureAir assets in February 2025. Subsequent to quarter‑end, 60,496,041 preferred shares converted to common and the related‑party note was converted into 31,939,778 common shares; as of October 27, 2025, common shares outstanding were 104,621,231.
Impact BioMedical, Inc. reported a six-month net loss of $15,631,000 for the period ended June 30, 2025, versus a loss of $1,880,000 a year earlier, driven primarily by a $12,942,000 fair-value adjustment on a related-party note payable. Operating loss for the six months was $2,165,000 while total revenue was nominal at $7,000, reflecting limited commercial sales activity.
At June 30, 2025, total assets were $19.06 million (including $17.565 million of net intangible assets for developed technologies), cash was $624,000, and the related-party note payable was recorded at $22.352 million. Stockholders' deficit was $10.341 million and accumulated deficit increased to $53.283 million. The company disclosed substantial doubt about its ability to continue as a going concern and noted it raised $3.726 million in its September 16, 2024 IPO. The company also completed a February 25, 2025 acquisition of DSS PureAir assets for $1.15 million paid in stock, adding inventory and Celios IP.